Literature DB >> 24502482

Nitinol self-expanding stents vs. balloon angioplasty for very long femoropopliteal lesions.

Ehrin J Armstrong1, Haseeb Saeed, Bejan Alvandi, Satinder Singh, Gagan D Singh, Khung Keong Yeo, David Anderson, Gregory G Westin, David L Dawson, William C Pevec, John R Laird.   

Abstract

PURPOSE: To compare the patency rates and clinical outcomes of balloon angioplasty vs. nitinol stent placement for patients with short (≤150 mm) as compared to long (>150 mm) femoropopliteal (FP) occlusive lesions.
METHODS: Between 2006 and 2011, 254 patients (134 men; mean age 68 years) underwent FP angioplasty. The majority of patients (64%) were treated for critical limb ischemia. One hundred thirty-nine (55%) patients had short FP lesions ≤150 mm, while 115 patients had long FP lesions >150 mm. The mean lesion length was 78±43 mm in the short FP lesion group and 254±58 mm in the long FP lesion group. Duplex ultrasound follow-up with a peak systolic velocity ratio ≥2.0 was used to define restenosis.
RESULTS: The overall procedure success rate was 98%. One hundred forty-eight (58%) patients underwent stent placement. The mean number of stents deployed for treatment of short FP lesions was 1.0±0.4 vs. 2.0±0.7 for long FP lesions (p<0.001). The primary patency rate of short FP lesions treated with balloon angioplasty vs. stenting was 66% vs. 63% at 1 year (p=0.7). For long FP lesions, the 1-year primary patency rates of balloon angioplasty vs. stenting were 34% vs. 49% (p=0.006). Balloon angioplasty of long FP lesions was also associated with significantly lower assisted primary and secondary patency compared to stenting (p<0.05 for all comparisons). Sustained clinical improvement was >90% at 30 days but declined to 62% to 75% at 1 year.
CONCLUSION: Balloon angioplasty and stent placement result in similar patency rates and clinical outcomes for shorter to medium-length FP lesions. In comparison, stent placement in long FP lesions is associated with superior outcomes to balloon angioplasty, even when multiple stents are required. Procedure success and clinical improvement can be achieved in the majority of patients, but rates of restenosis remain high.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24502482      PMCID: PMC8922726          DOI: 10.1583/13-4399MR.1

Source DB:  PubMed          Journal:  J Endovasc Ther        ISSN: 1526-6028            Impact factor:   3.487


  28 in total

1.  Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg.

Authors:  Gunnar Tepe; Thomas Zeller; Thomas Albrecht; Stephan Heller; Uwe Schwarzwälder; Jean-Paul Beregi; Claus D Claussen; Anja Oldenburg; Bruno Scheller; Ulrich Speck
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

2.  Long-segment SFA stenting--the dark sides: in-stent restenosis, clinical deterioration, and stent fractures.

Authors:  Oliver Schlager; Petra Dick; Schila Sabeti; Jasmin Amighi; Wolfgang Mlekusch; Erich Minar; Martin Schillinger
Journal:  J Endovasc Ther       Date:  2005-12       Impact factor: 3.487

3.  Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions.

Authors:  Petra Dick; Hubert Wallner; Schila Sabeti; Christian Loewe; Wolfgang Mlekusch; Johannes Lammer; Renate Koppensteiner; Erich Minar; Martin Schillinger
Journal:  Catheter Cardiovasc Interv       Date:  2009-12-01       Impact factor: 2.692

4.  Clinical outcomes and implications of failed infrainguinal endovascular stents.

Authors:  Ilia Gur; William Lee; Gabriel Akopian; Vincent L Rowe; Fred A Weaver; Steven G Katz
Journal:  J Vasc Surg       Date:  2011-01-22       Impact factor: 4.268

5.  Gender-related variation in the clinical presentation and outcomes of critical limb ischemia.

Authors:  Caroline E McCoach; Ehrin J Armstrong; Satinder Singh; Usman Javed; David Anderson; Khung Keong Yeo; Gregory G Westin; Nasim Hedayati; Ezra A Amsterdam; John R Laird
Journal:  Vasc Med       Date:  2013-02       Impact factor: 3.239

6.  Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).

Authors:  Johannes Lammer; Thomas Zeller; Klaus A Hausegger; Philipp J Schaefer; Manfred Gschwendtner; Stefan Mueller-Huelsbeck; Thomas Rand; Martin Funovics; Florian Wolf; Aljoscha Rastan; Michael Gschwandtner; Stefan Puchner; Robin Ristl; Maria Schoder
Journal:  J Am Coll Cardiol       Date:  2013-07-10       Impact factor: 24.094

7.  Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses.

Authors:  Osamu Iida; Masaaki Uematsu; Yoshimitsu Soga; Keisuke Hirano; Kenji Suzuki; Hiroyoshi Yokoi; Toshiya Muramatsu; Naoto Inoue; Shinsuke Nanto; Seiki Nagata
Journal:  Catheter Cardiovasc Interv       Date:  2011-07-29       Impact factor: 2.692

8.  Randomized trial of the SMART stent versus balloon angioplasty in long superficial femoral artery lesions: the SUPER study.

Authors:  Nicholas Chalmers; Paul T Walker; Anna-Maria Belli; Anthony P Thorpe; Paul S Sidhu; Graham Robinson; Mariella van Ransbeeck; Steven A Fearn
Journal:  Cardiovasc Intervent Radiol       Date:  2012-10-16       Impact factor: 2.740

9.  Clinical follow-up in endovascular treatment for TASC C-D lesions in femoro-popliteal segment.

Authors:  Martin Rabellino; Tobias Zander; Sebastian Baldi; Luis Garcia Nielsen; F Javier Aragon-Sanchez; Ignacio Zerolo; Rafael Llorens; Manuel Maynar
Journal:  Catheter Cardiovasc Interv       Date:  2009-04-01       Impact factor: 2.692

10.  Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results.

Authors:  Michael D Dake; Gary M Ansel; Michael R Jaff; Takao Ohki; Richard R Saxon; H Bob Smouse; Thomas Zeller; Gary S Roubin; Mark W Burket; Yazan Khatib; Scott A Snyder; Anthony O Ragheb; J King White; Lindsay S Machan
Journal:  Circ Cardiovasc Interv       Date:  2011-09-27       Impact factor: 6.546

View more
  8 in total

1.  Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial.

Authors:  Gunnar Tepe; John Laird; Peter Schneider; Marianne Brodmann; Prakash Krishnan; Antonio Micari; Christopher Metzger; Dierk Scheinert; Thomas Zeller; David J Cohen; David B Snead; Beaux Alexander; Mario Landini; Michael R Jaff
Journal:  Circulation       Date:  2014-12-03       Impact factor: 29.690

2.  Stellarex drug-coated balloon for treatment of femoropopliteal arterial disease-The ILLUMENATE Global Study: 12-Month results from a prospective, multicenter, single-arm study.

Authors:  Herman Schroë; Andrew H Holden; Yann Goueffic; Shirley J Jansen; Patrick Peeters; Koen Keirse; Wulf Ito; Frank Vermassen; Antonio Micari; Erwin Blessing; Michael R Jaff; Thomas Zeller
Journal:  Catheter Cardiovasc Interv       Date:  2017-10-31       Impact factor: 2.692

3.  The Randomized Freeway Stent Study: Drug-Eluting Balloons Outperform Standard Balloon Angioplasty for Postdilatation of Nitinol Stents in the SFA and PI Segment.

Authors:  Josef Tacke; Stephan Müller-Hülsbeck; Henrik Schröder; Johannes Lammer; Karl Schürmann; Walter Gross-Fengels; Roman Fischbach; Jochen Textor; Lothar Boguth; Christian Loewe; Hannes Häuser; Manfred Gschwendtner; Gunnar Tepe; Rembert Pogge von Strandmann; Stefanie Stahnke; Johannes Dambach; Klaus Hausegger
Journal:  Cardiovasc Intervent Radiol       Date:  2019-08-20       Impact factor: 2.740

4.  Excimer laser atherectomy combined with drug-coated balloon angioplasty for the treatment of chronic obstructive femoropopliteal arterial disease.

Authors:  Hui Liu; Yan Gu; Sen Yang; Ju He; Fuxian Zhang
Journal:  Exp Ther Med       Date:  2019-12-20       Impact factor: 2.447

5.  Paclitaxel-coated balloons angioplasties for extra-long femoropopliteal artery atherosclerotic lesions (> 30 ​cm):12 months outcomes from a single center.

Authors:  Tao Pan; Guodong Zhang; Zhen Liu; Tao Zhang; Cheng Li; Donghua Ji
Journal:  J Interv Med       Date:  2022-02-26

6.  Feasibility and Clinical Outcomes of Peripheral Drug-Coated Balloon in High-Risk Patients with Femoropopliteal Disease.

Authors:  Shih-Jung Jang; Chien-An Hsieh; Hsuan-Li Huang; Jyh-Ming Jimmy Juang; Hsin-Hua Chou; Chueh-Yung Tsao; Tien-Yu Wu; Yu-Lin Ko
Journal:  PLoS One       Date:  2015-11-24       Impact factor: 3.240

7.  Clinical impact and risk stratification of balloon angioplasty for femoropopliteal disease in nitinol stenting era: Retrospective multicenter study using propensity score matching analysis.

Authors:  Taketsugu Tsuchiya; Takaaki Takamura; Yoshimitsu Soga; Osamu Iida; Keisuke Hirano; Kenji Suzuki; Terutoshi Yamaoka; Yusuke Miyashita; Michihiko Kitayama; Koji Kajinami
Journal:  SAGE Open Med       Date:  2016-07-18

8.  In-Stent Restenosis Progression in Human Superficial Femoral Arteries: Dynamics of Lumen Remodeling and Impact of Local Hemodynamics.

Authors:  Monika Colombo; Yong He; Anna Corti; Diego Gallo; Federica Ninno; Stefano Casarin; Jared M Rozowsky; Francesco Migliavacca; Scott Berceli; Claudio Chiastra
Journal:  Ann Biomed Eng       Date:  2021-04-29       Impact factor: 3.934

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.